(FLGT) Fulgent Genetics - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 486m USD | Total Return: -12.5% in 12m
Avg Turnover: 7.95M
Qual. Beats: 0
Rev. Trend: 60.7%
Qual. Beats: 1
Warnings
High Debt while negative Cash Flow
Interest Coverage Ratio -422.0 is critical
Extended 1w
Tailwinds
No distinct edge detected
Fulgent Genetics, Inc. (FLGT) operates a dual-model business providing clinical diagnostics and therapeutic development. The company utilizes a proprietary technology platform consisting of gene probes and adaptive learning software to offer molecular testing, anatomic pathology, and oncology diagnostics. Its therapeutic division focuses on nanoencapsulation technology designed to improve the delivery and efficacy of cancer drugs.
The clinical laboratory sector is characterized by high capital expenditures and a shift toward Next-Generation Sequencing (NGS), which allows for the simultaneous testing of multiple genetic variants. Fulgent’s integrated laboratory information management system enables the processing of complex genomic data for a diverse client base including hospitals, government bodies, and pharmaceutical corporations.
Investors can further evaluate the companys valuation metrics and growth trajectory on ValueRay. Fulgent Genetics, headquartered in El Monte, California, transitioned from its original name, Fulgent Diagnostics, in 2016 to reflect its broader focus on genetic intelligence and drug development.
- Precision oncology and reproductive health testing volume drives core clinical revenue growth
- Expansion into therapeutic drug development increases research and development capital expenditure
- Medicare reimbursement rate changes impact margins for anatomic pathology and genetic testing
- Strategic acquisitions and laboratory consolidations determine long-term operational efficiency and scale
| Net Income: -73.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA -7.16 > 1.0 |
| NWC/Revenue: 121.4% < 20% (prev 120.0%; Δ 1.43% < -1%) |
| CFO/TA -0.08 > 3% & CFO -90.1m > Net Income -73.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.9m) vs 12m ago 0.16% < -2% |
| Gross Margin: 38.71% > 18% (prev 0.39%; Δ 3.83k% > 0.5%) |
| Asset Turnover: 27.12% > 50% (prev 24.25%; Δ 2.87% > 0%) |
| Interest Coverage Ratio: -422.0 > 6 (EBITDA TTM -58.5m / Interest Expense TTM 196k) |
| A: 0.34 (Total Current Assets 479.0m - Total Current Liabilities 90.1m) / Total Assets 1.16b |
| B: 0.44 (Retained Earnings 505.1m / Total Assets 1.16b) |
| C: -0.07 (EBIT TTM -82.7m / Avg Total Assets 1.18b) |
| D: 4.54 (Book Value of Equity 509.7m / Total Liabilities 112.2m) |
| Altman-Z'' = 7.93 = AAA |
| DSRI: 0.86 (Receivables 75.7m/80.4m, Revenue 320.3m/292.4m) |
| GMI: 1.00 (GM 38.71% / 38.80%) |
| AQI: 0.85 (AQ_t 0.48 / AQ_t-1 0.57) |
| SGI: 1.10 (Revenue 320.3m / 292.4m) |
| TATA: 0.01 (NI -73.8m - CFO -90.1m) / TA 1.16b) |
| Beneish M = -3.15 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 17.67 with a total of 398,075 shares traded.
Over the past week, the price has changed by +11.48%,
over one month by +13.27%,
over three months by -28.63% and
over the past year by -12.48%.
Fulgent Genetics has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold FLGT.
- StrongBuy: 0
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.5 | 4.7% |
P/E Forward = 7.7042
P/S = 1.5169
P/B = 0.463
P/EG = 1.32
Revenue TTM = 320.3m USD
EBIT TTM = -82.7m USD
EBITDA TTM = -58.5m USD
Long Term Debt = 1.48m USD (from longTermDebt, last quarter)
Short Term Debt = 2.69m USD (from shortTermDebt, last quarter)
Debt = 18.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.94m
Net Debt = -258.2m USD (calculated: Debt 18.1m - CCE 276.3m)
Enterprise Value = 227.7m USD (485.9m + Debt 18.1m - CCE 276.3m)
Interest Coverage Ratio = -422.0 (Ebit TTM -82.7m / Interest Expense TTM 196k)
EV/FCF = -2.01x (Enterprise Value 227.7m / FCF TTM -113.2m)
FCF Yield = -49.69% (FCF TTM -113.2m / Enterprise Value 227.7m)
FCF Margin = -35.33% (FCF TTM -113.2m / Revenue TTM 320.3m)
Net Margin = -23.04% (Net Income TTM -73.8m / Revenue TTM 320.3m)
Gross Margin = 38.71% ((Revenue TTM 320.3m - Cost of Revenue TTM 196.3m) / Revenue TTM)
Gross Margin QoQ = 30.21% (prev 39.10%)
Tobins Q-Ratio = 0.20 (Enterprise Value 227.7m / Total Assets 1.16b)
Interest Expense / Debt = 1.08% (Interest Expense 196k / Debt 18.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -65.3m (EBIT -82.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.31 (Total Current Assets 479.0m / Total Current Liabilities 90.1m)
Debt / Equity = 0.02 (Debt 18.1m / totalStockholderEquity, last quarter 1.05b)
Debt / EBITDA = 4.41 (negative EBITDA) (Net Debt -258.2m / EBITDA -58.5m)
Debt / FCF = 2.28 (negative FCF - burning cash) (Net Debt -258.2m / FCF TTM -113.2m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.25% (Net Income -73.8m / Total Assets 1.16b)
RoE = -6.70% (Net Income TTM -73.8m / Total Stockholder Equity 1.10b)
RoCE = -7.50% (EBIT -82.7m / Capital Employed (Equity 1.10b + L.T.Debt 1.48m))
RoIC = -7.76% (negative operating profit) (NOPAT -65.3m / Invested Capital 842.2m)
WACC = 6.90% (E(485.9m)/V(504.0m) * Re(7.13%) + D(18.1m)/V(504.0m) * Rd(1.08%) * (1-Tc(0.21)))
Discount Rate = 7.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.54 | Cagr: 1.47%
[DCF] Fair Price = unknown (Cash Flow -113.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.04 | # QB: 0
Revenue Correlation: 60.74 | Revenue CAGR: 3.47% | SUE: 1.31 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.44 | Chg30d=-38.25% | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=-45.45% | Revisions=N/A | Analysts=2
EPS current Year (2026-12-31): EPS=-1.57 | Chg30d=-11.48% | Revisions=-20% | GrowthEPS=-473.4% | GrowthRev=+8.8%
EPS next Year (2027-12-31): EPS=-1.53 | Chg30d=-2.89% | Revisions=-20% | GrowthEPS=+2.6% | GrowthRev=+14.6%
[Analyst] Revisions Ratio: -20%